Pivotal Multiple Myeloma, Leukemia Trials May Not Represent the Populations They Serve
Investigators identified underrepresentation and imbalances in demographic and geographic representation in clinical trials leading to FDA approvals.
Investigators identified underrepresentation and imbalances in demographic and geographic representation in clinical trials leading to FDA approvals.
A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.
Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.
After reviewing the evidence, nurses switched from heparin-based flushes to all saline flushes for patients disconnecting chemotherapy at home.
The journey toward vicarious resilience is not only possible but essential—for ourselves, our patients, and it is the very essence of health care.
Patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with nadofaragene firadenovec experienced lasting responses to the therapy for up to 3 years.
Durvalumab monotherapy as consolidation therapy in limited-stage small cell lung cancer produced a clinical benefit in patients from the phase 3 ADRIATIC trial.
The final breast cancer screening recommendation from the United States Preventive Services Task Force advises that women aged 40 should begin biennial screening.
An oncology nurse explains how her institution created a surgical path card that improved wait times and patient satisfaction in adults undergoing cancer surgery.
The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.
In this episode of The Vitals, we speak with an expert who discussed the importance of supportive care and education for patients with lung cancer…